FDA Approves Mounjaro to Cut Cardiovascular Risk in Type 2 Diabetes

Eli Lilly’s Mounjaro (tirzepatide) can now claim a cardiovascular benefit. The FDA on August 28 approved the drug to reduce the risk of major adverse cardiovascular events, defined as cardiovascular death, heart attack, or stroke, in adults with type 2 diabetes at high risk. Mounjaro becomes the first dual GIP/GLP-1 receptor agonist cleared for cardiovascular risk reduction, closing a label gap with Novo Nordisk’s semaglutide franchise, which already carries a CV indication. Lilly (LLY) shares were essentially flat, last near $1,175, reflecting both the company’s roughly $900 billion size and a label expansion the market had long expected.

Tirzepatide works by activating two incretin hormone receptors, GIP and GLP-1, which the body uses to regulate blood sugar and appetite. The approval rests on SURPASS-CVOT, a roughly 13,000-patient, event-driven head-to-head trial pitting tirzepatide against Lilly’s own Trulicity (dulaglutide) in people with type 2 diabetes and established atherosclerotic disease. That design is notable: it is the first cardiovascular outcomes trial to compare two incretin therapies directly rather than testing one against placebo.

Tirzepatide met the primary non-inferiority objective with an 8% lower rate of MACE-3 events (hazard ratio 0.92; 95.3% CI, 0.83 to 1.01). All-cause death was 16% lower (HR 0.84). In a pre-specified indirect comparison against placebo, tirzepatide showed a 28% reduction in MACE (HR 0.72) and a 39% reduction in all-cause mortality (HR 0.61).

Those placebo-relative figures are the headline, but they carry a caveat: the trial was not placebo-controlled. The primary bar was non-inferiority versus dulaglutide, itself a GLP-1 with proven CV benefit. So Mounjaro cleared the hurdle by proving it is at least as good as an already-protective comparator, not by beating placebo in a clean head-to-head. Investors reading “39% mortality reduction” should know it is an indirect estimate.

The safety profile held no surprises. Gastrointestinal side effects were the most common in both arms and were mostly mild to moderate, resolving after dose escalation. Treatment discontinuation was modestly higher on tirzepatide at 13.3% versus 10.2% on dulaglutide. Tirzepatide is the same molecule sold as Zepbound for obesity and obstructive sleep apnea, so a CV label on the diabetes brand rounds out a franchise Lilly is betting heavily on.

Still, the label is what matters commercially. A CV indication unlocks cardiologist prescribing and reinforces Medicare Part D positioning for what is already the most-prescribed branded type 2 diabetes medicine in the US. For Lilly, it adds a second differentiator beyond weight loss in the metabolic arms race with Novo.

The next thing to watch is whether Zepbound, tirzepatide’s obesity brand, wins a CV label of its own. Novo’s Wegovy already owns the obesity-CV story through the SELECT trial. Here is how the GLP-1 market breaks down, and the cardiometabolic catalysts to watch this year.

Source: Lilly press release